The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis
about
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistanceNew insights into TB physiology suggest untapped therapeutic opportunitiesMethylfolate Trap Promotes Bacterial Thymineless Death by Sulfa DrugsCo-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.Tuberculosis treatment and drug regimens.Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistanceMycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction.The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristicsThe potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosisAnti-folates potentiate bactericidal effects of other antimicrobial agents.Collateral Resistance and Sensitivity Modulate Evolution of High-Level Resistance to Drug Combination Treatment in Staphylococcus aureus.Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.Identification of antimicrobial activity among new sulfonamide metal complexes for combating rapidly growing mycobacteria.dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains.Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes.
P2860
Q28082718-2495B862-A29F-4ECD-A846-7035482BE30EQ28388477-48EA3629-FE1E-46F6-A493-B8392A04D647Q28552781-A9B986FF-169D-439D-BE63-145D582C26EAQ33622785-62B6E29D-D3D3-44FD-915D-F1DEF7260626Q35663866-6C002C0D-4AB8-46B4-9E48-E848A638AC3DQ35960967-E3ABD75C-3D0F-428D-98C3-0B4565519E52Q36396241-5EF087D7-A665-4961-B07B-3A6CA8D9C69BQ36973888-4CA417C0-58B9-493E-ABEA-6FB0EE232413Q37712989-1D39F06E-E7E1-43F0-B6BF-37A48CAA74D4Q38806183-4F7787AB-9BEE-4009-958B-AA488F58A0B7Q38954085-DDE0BE9F-42A7-45EC-B0ED-A9D65BDF7701Q39028198-6F519950-C4AA-4772-9263-BAF06C766A5BQ39050661-FABF490B-BECD-4153-9B8E-3A569EB4D122Q40343712-EEDE8307-4FB0-40A1-ABEE-EA3DD84D314AQ40560940-2139B8ED-6D3A-4A81-B565-13EF42902B91Q42763782-3D3C4E54-D26A-414D-971C-50BFDD096CDBQ42872195-AB0E9920-DE76-4421-8F82-B93E46A827F0
P2860
The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@ast
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@en
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@nl
type
label
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@ast
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@en
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@nl
prefLabel
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@ast
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@en
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@nl
P2860
P3181
P356
P1476
The combination of sulfamethox ...... in Mycobacterium tuberculosis
@en
P2093
Catherine Vilchèze
William R Jacobs
P2860
P304
P3181
P356
10.1128/AAC.00832-12
P407
P577
2012-10-01T00:00:00Z